UroGen Pharma (URGN) Asset Utilization Ratio (2018 - 2026)
UroGen Pharma (URGN) posted quarterly Asset Utilization Ratio of 0.62 for Q1 2026, up 79.59% year-on-year from 0.34 in Q1 2025, and up 8.63% on a QoQ basis from 0.57 in Q4 2025.
UroGen Pharma (URGN) Asset Utilization Ratio (2018 - 2026) Analysis & Trends
UroGen Pharma (URGN) has reported Asset Utilization Ratio for 9 consecutive years, with 0.62 the latest figure, recorded in Q1 2026.
- Quarterly Asset Utilization Ratio rose 79.59% year-over-year to 0.62 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.62 (up 79.59% YoY) and the FY2025 annual result came in at 0.45, up 15.92% from the prior year.
- Asset Utilization Ratio improved to 0.62 in Q1 2026 per URGN's latest filing, from 0.57 in the prior quarter.
- Over the last five years, Asset Utilization Ratio for URGN reached as high as 0.7 in Q2 2023 and fell as low as 0.31 in Q3 2024.
- A 5-year average of 0.46 and a median of 0.45 in 2024 frame the typical range for Asset Utilization Ratio.
- Annual changes were most pronounced in 2022 — Asset Utilization Ratio jumped 115.72% — and 2024, when it slumped 49.38%.
- Year by year, Asset Utilization Ratio stood at 0.49 in 2022, then fell by 8.75% to 0.44 in 2023, then slumped by 30.83% to 0.31 in 2024, then surged by 85.14% to 0.57 in 2025, then advanced by 8.63% to 0.62 in 2026.
- According to Business Quant data, Asset Utilization Ratio over the past three periods registered 0.62, 0.57, and 0.49 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 0.69 |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 0.47 |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 0.37 |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | UroGen Pharma | 2.13 Bn | 1.99 Bn | 46.82 Mn | 0.62 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.62 |
| Dec 31, 2025 | 0.57 |
| Sep 30, 2025 | 0.49 |
| Jun 30, 2025 | 0.41 |
| Mar 31, 2025 | 0.34 |
| Dec 31, 2024 | 0.31 |
| Sep 30, 2024 | 0.31 |
| Jun 30, 2024 | 0.35 |
| Mar 31, 2024 | 0.45 |
| Dec 31, 2023 | 0.44 |
| Sep 30, 2023 | 0.53 |
| Jun 30, 2023 | 0.70 |
| Mar 31, 2023 | 0.55 |
| Dec 31, 2022 | 0.49 |
| Sep 30, 2022 | 0.45 |
| Jun 30, 2022 | 0.37 |
| Mar 31, 2022 | 0.38 |
| Dec 31, 2021 | 0.38 |
| Sep 30, 2021 | 0.28 |
| Jun 30, 2021 | 0.25 |